Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
84% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. ALNY: No Debt )
ALNY' s 10-Year Cash to Debt Range
Min: 3.29   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ALNY's Equity to Asset is ranked higher than
93% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ALNY: 0.91 )
ALNY' s 10-Year Equity to Asset Range
Min: -0.99   Max: 0.91
Current: 0.91

-0.99
0.91
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
83% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
ALNY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 31.49
M-Score: -4.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -197.05
ALNY's Operating margin (%) is ranked higher than
64% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. ALNY: -197.05 )
ALNY' s 10-Year Operating margin (%) Range
Min: -14236.93   Max: -28.95
Current: -197.05

-14236.93
-28.95
Net-margin (%) -189.17
ALNY's Net-margin (%) is ranked higher than
65% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ALNY: -189.17 )
ALNY' s 10-Year Net-margin (%) Range
Min: -14223.3   Max: -27.3
Current: -189.17

-14223.3
-27.3
ROE (%) -33.00
ALNY's ROE (%) is ranked higher than
68% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ALNY: -33.00 )
ALNY' s 10-Year ROE (%) Range
Min: -79.08   Max: -12.99
Current: -33

-79.08
-12.99
ROA (%) -21.22
ALNY's ROA (%) is ranked higher than
70% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. ALNY: -21.22 )
ALNY' s 10-Year ROA (%) Range
Min: -71.15   Max: -4.73
Current: -21.22

-71.15
-4.73
ROC (Joel Greenblatt) (%) -565.07
ALNY's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. ALNY: -565.07 )
ALNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -802.66   Max: -145.02
Current: -565.07

-802.66
-145.02
Revenue Growth (%) -31.40
ALNY's Revenue Growth (%) is ranked higher than
63% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ALNY: -31.40 )
ALNY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 108
Current: -31.4

0
108
EBITDA Growth (%) 13.80
ALNY's EBITDA Growth (%) is ranked higher than
88% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ALNY: 13.80 )
ALNY' s 10-Year EBITDA Growth (%) Range
Min: -64.8   Max: 36.5
Current: 13.8

-64.8
36.5
EPS Growth (%) 11.70
ALNY's EPS Growth (%) is ranked higher than
88% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. ALNY: 11.70 )
ALNY' s 10-Year EPS Growth (%) Range
Min: -66.7   Max: 28.6
Current: 11.7

-66.7
28.6
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALNY Guru Trades in Q3 2013

Vanguard Health Care Fund 576,800 sh (New)
Columbia Wanger 1,314,856 sh (+19.75%)
Steven Cohen 65,000 sh (-89.52%)
» More
Q4 2013

ALNY Guru Trades in Q4 2013

Vanguard Health Care Fund 4,105,200 sh (+611.72%)
Columbia Wanger 1,910,000 sh (+45.26%)
Steven Cohen 45,435 sh (-30.1%)
» More
Q1 2014

ALNY Guru Trades in Q1 2014

Jim Simons 158,700 sh (New)
George Soros 3,092 sh (New)
Steven Cohen 140,522 sh (+209.28%)
Vanguard Health Care Fund 4,524,800 sh (+10.22%)
Columbia Wanger 902,764 sh (-52.73%)
» More
Q2 2014

ALNY Guru Trades in Q2 2014

Vanguard Health Care Fund 4,973,900 sh (+9.93%)
Jim Simons Sold Out
George Soros Sold Out
Columbia Wanger 784,500 sh (-13.1%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $48.87 - $70.76 $ 68.0515%0
George Soros 2014-03-31 New Buy$61.07 - $93.28 $ 68.05-12%3092
Vanguard Health Care Fund 2013-12-31 Add 611.72%0.7%$50.79 - $66.91 $ 68.0514%4105200
Vanguard Health Care Fund 2013-09-30 New Buy0.13%$35.84 - $64.07 $ 68.0536%576800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.50
ALNY's P/B is ranked higher than
64% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ALNY: 5.50 )
ALNY' s 10-Year P/B Range
Min: 1.58   Max: 21.28
Current: 5.5

1.58
21.28
P/S 129.87
ALNY's P/S is ranked lower than
67% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. ALNY: 129.87 )
ALNY' s 10-Year P/S Range
Min: 3.09   Max: 132.09
Current: 129.87

3.09
132.09
Current Ratio 12.38
ALNY's Current Ratio is ranked higher than
91% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. ALNY: 12.38 )
ALNY' s 10-Year Current Ratio Range
Min: 1.88   Max: 12.38
Current: 12.38

1.88
12.38
Quick Ratio 12.38
ALNY's Quick Ratio is ranked higher than
91% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALNY: 12.38 )
ALNY' s 10-Year Quick Ratio Range
Min: 1.88   Max: 12.38
Current: 12.38

1.88
12.38

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.10
ALNY's Price/Net Cash is ranked higher than
77% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALNY: 9.10 )
ALNY' s 10-Year Price/Net Cash Range
Min: 3.7   Max: 92.77
Current: 9.1

3.7
92.77
Price/Net Current Asset Value 9.10
ALNY's Price/Net Current Asset Value is ranked higher than
75% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. ALNY: 9.10 )
ALNY' s 10-Year Price/Net Current Asset Value Range
Min: 3.61   Max: 91.44
Current: 9.1

3.61
91.44
Price/Tangible Book 5.50
ALNY's Price/Tangible Book is ranked higher than
70% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. ALNY: 5.50 )
ALNY' s 10-Year Price/Tangible Book Range
Min: 2.2   Max: 15.09
Current: 5.5

2.2
15.09
Price/Median PS Value 6.80
ALNY's Price/Median PS Value is ranked lower than
59% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ALNY: 6.80 )
ALNY' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 6.26
Current: 6.8

0.18
6.26
Forward Rate of Return (Yacktman) 33.98
ALNY's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ALNY: 33.98 )
ALNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 38.4   Max: 62.6
Current: 33.98

38.4
62.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany
Alnylam Pharmaceuticals, Inc. is a Delaware corporation that was formed in May 2003. It comprises four entities, Alnylam Pharmaceuticals, Inc. and its three wholly owned subsidiaries: Alnylam U.S., Inc., Alnylam Europe AG and Alnylam Securities Corporation. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a range of human diseases. Drugs that work through RNAi have the potential to become a new class of drugs, like small molecule, protein and antibody drugs. Using its intellectual property and the expertise the company has built in RNAi, it is developing a set of biological and chemical methods and know-how that it applies in a systematic way to develop RNAi therapeutics for a number of diseases. The company is applying its technological expertise to build a pipeline of RNAi therapeutics to address medical needs. Its RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus, or RSV, infection, which is reported to be the main cause of hospitalization in infants in the United States and also occurs in the elderly and in immune compromised adults. The company is also working on a number of programs in pre-clinical development, including ALN-VSP, ALN-PCS, ALN-TTR and ALN-HTT, focused on the treatment of hypercholesterolemia, transthyretin, or TTR, amyloidosis, and Huntington's disease, respectively. In addition, it is working internally and with third-party collaborators to develop capabilities to deliver its RNAi therapeutics directly to specific sites of disease, such as the delivery of ALN-RSV01 to the lungs. It is also working to extend its capabilities to advance the development of RNAi therapeutics that are administered by intravenous, subcutaneous or intramuscular approaches. The company has numerous RNAi therapeutic delivery collaborations and intends to continue to collaborate with government, academic and corporate third parties to evaluate different delivery options, including with respect to Direct RNAi and Systemic RNAi. The company's expertise in RNAi therapeutics and intellectual property estate has allowed it to form alliances with companies, including Isis Pharmaceuticals, Inc., Medtronic, Inc., NovartisPharma AG, Biogen Idec Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Kyowa Hakko and Cubist. It has also entered into contracts with government agencies, including the National Institute of Allergy and Infectious Diseases, or NIAID, a component of the National Institutes of Health, or NIH. It also seeks opportunities to form new ventures in areas outside its core strategic interes

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide